Alexion Pharmaceuticals Inc., of New Haven, Conn., reported fourth-quarter revenues totaling $909.7 million, beating consensus estimates of $880.6 million. For the full year, revenues totaled $3.551 billion. On a GAAP basis, diluted earnings per share (EPS) for the quarter was 13 cents per share, while EPS for the full year was $1.97 per share.